RESEARCH ARTICLE

Novel flowcytometry-based approach of malignant cell detection in body fluids using an automated hematology analyzer

Tomohiko Ai¹,², Yoko Tabe¹,², Hiroyuki Takeura³, Konobu Kimura¹,⁴, Toshihiro Takahashi³, Haeun Yang², Koji Tsuchiya³,⁵, Aya Konishi⁴, Kinya Uchihashi⁴, Takashi Hori³, Akimichi Ohsaka¹,³,⁵

¹ Department of Next Generation Hematology Laboratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan, ² Department of Clinical Laboratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan, ³ Department of Clinical Laboratory, Juntendo University Hospital, Tokyo, Japan, ⁴ Sysmex, Hematology-Product Engineering, Product Development, Kobe, Japan, ⁵ Department of Transfusion Medicine and Stem Cell Regulation, Juntendo University Graduate School of Medicine, Tokyo, Japan

* tabe@juntendo.ac.jp

Abstract

Morphological microscopic examinations of nucleated cells in body fluid (BF) samples are performed to screen malignancy. However, the morphological differentiation is time-consuming and labor-intensive. This study aimed to develop a new flowcytometry-based gating analysis mode “XN-BF gating algorithm” to detect malignant cells using an automated hematology analyzer, Sysmex XN-1000. XN-BF mode was equipped with WDF white blood cell (WBC) differential channel. We added two algorithms to the WDF channel: Rule 1 detects larger and clumped cell signals compared to the leukocytes, targeting the clustered malignant cells; Rule 2 detects middle sized mononuclear cells containing less granules than neutrophils with similar fluorescence signal to monocytes, targeting hematological malignant cells and solid tumor cells. BF samples that meet, at least, one rule were detected as malignant. To evaluate this novel gating algorithm, 92 various BF samples were collected. Manual microscopic differentiation with the May–Grunwald Giemsa stain and WBC count with hemocytometer were also performed. The performance of these three methods were evaluated by comparing with the cytological diagnosis. The XN-BF gating algorithm achieved sensitivity of 63.0% and specificity of 87.8% with 68.0% for positive predictive value and 85.1% for negative predictive value in detecting malignant-cell positive samples. Manual microscopic WBC differentiation and WBC count demonstrated 70.4% and 66.7% of sensitivities, and 96.9% and 92.3% of specificities, respectively. The XN-BF gating algorithm can be a feasible tool in hematology laboratories for prompt screening of malignant cells in various BF samples.
Introduction

Differentiation of nucleated cells including malignant cells in various body fluid (BF) samples is an essential technique to determine the clinical treatment strategies. A positive effusion for malignant cells is an important indicator in the diagnosis of malignant lesions and staging [1]. Therefore, the examination of BF for the presence of malignant cells has been accepted as a routine laboratory procedure, not only for the detection of incidental malignancy, but also for the detection of metastasis of an unknown primary origin [1, 2]. Especially, cytological examinations with papanicolaou and immunohistochemical stainings performed in pathology laboratories are of paramount importance in the diagnosis of malignancy in BF samples [2–4]. However, the routine cytology results are not available in the same day when the samples are sent to the lab, which prevents physicians from making a quick diagnosis. Hence, it is expected that the screening of malignant cells by the hematological examinations enables a rapid report to physicians and might be useful as adjunct rapid diagnosis tests. For example, in the differential diagnosis of coma patients, rapid automated analysis of CSF samples can benefit physicians’ quick decision making [5]. Prompt detection of malignant cells in body fluid samples including bloods may be useful for the diagnosis of disseminated intravascular coagulation [6].

Although manual microscopic examinations are most widely used in hematology laboratories, those are time consuming and results are sometimes hampered by inter-examiners’ variability in their skill levels. To date, many scientists and industries have been attempting to develop automated analyzing systems, and several different algorithms of the automated hematology analyzers have been developed to count and differentiate nucleated cells in various BF samples such as synovial, cerebrospinal, pleural, ascitic and pericardial fluids [7–10]. However, detection of malignant cells in BF samples by the hematology analyzers is still challenging because cell size, shape and cytoplasmic density of malignant cells vary as well as malignant cells often stick each other and form clumps.

Recently, a new detection mode, called high-fluorescence body fluid (HF-BF) [8, 11], has been equipped to the automatic hematoanalyzer Sysmex XN series (Sysmex, Kobe, Japan) perusing to discriminate non-haematopoietic cells. However, the nonmalignant cells such as mesothelial cells or macrophages are counted as the HF-BF cells along with malignant cells, and current HF-BF based analysis still causes false-positive results frequently. Thus, further improvement of the HF-BF to realize more accurate detection of malignant cells by modification of its parameter setting are warranted.

In this study, we propose a new XN-BF gating algorithm to detect malignant cells by modification of the conventional HF-BF algorithm. Specifically, two gating parameters, Rule 1 and Rule 2, based on the WDF channel were combined with HF-BF: (1) Rule 1 detects signals from large cells and clumped cells of which the most cells are consisted of clustered malignant cells; and (2) Rule 2 detects middle sized mononuclear cells with less granules than neutrophils and similar fluorescence signal to monocytes of which the most cells are consisted of hematological malignant cells and solid tumor cells. This novel algorithm was tested using various BF samples with and without malignant cells, and was evaluated by comparing with the cytological diagnosis in pathology laboratory.

Materials and methods

Patient samples

Between August 2013 and July 2014, a total of 92 BF samples were sent from different departments to the clinical laboratory of Juntendo University Hospital (Tokyo, Japan). The samples included 18 cerebrospinal fluid (CSF), 68 pleural effusion (PE) and 6 ascitic fluids for routine
diagnosis of malignancy. The samples were stored in K$_2$-EDTA tubes or sterile recipients without anticoagulant and requested to be sent to the laboratory immediately after collection. After arrival, automated analysis, manual microscopic WBC count and preparation of slides for microscopic cell differentiation were completed in hematology laboratory within two hours. Cytological examinations were performed at the pathology laboratory for these 92 BF samples. The study protocol was approved by the institutional review board of Juntendo University Hospital. Since all samples were de-identified, providing written informed consents to each patient was waved by the committee.

**Cell analyses by BF mode on the Sysmex XN hematology analyzer**

The XN-series analyzers are fully automated hematology analyzers equipped with dedicated BF measurement modes. To count and differentiate nucleated cells in BF, the cell membranes are perforated with Lysercell WDF™ (Sysmex, Kobe, Japan), then intracellular organelles and nucleic acids are stained with Fluorocell WDF™ (Sysmex, Kobe, Japan) so that the fluorescence flow cytometric analyses can detect specific side scattered signals which are generated depending on the type and quantity of intracellular organelles and nucleic acids. After treatments with these buffers, leukocytes rarely aggregate, and platelets are usually lysed (data not shown). Very small residual platelet and fibrin aggregates are almost negligible to affect forward scatter signals.

All BF samples were first analyzed by the BF mode of the XN-1000 Sysmex hematology analyzer (XN-BF) according to the manufacture’s protocol. If clots or fibrins were observed, they were manually removed. The XN-BF mode utilizes the WBC differential (WDF) channel that simultaneously generates four signals of each cell passing through the focused laser beam in Flowcell (i.e., detecting chamber): (1) forward scatter signals indicating the volume of the cell; (2) side scatter signals providing the information about intracellular structures and contents such as nucleus and granules; (3) fluorescence intensity signals indicating the amount of intracellular nucleic acids (i.e., DNA and RNA) presenting in the cell; and (4) the forward scatter width signals providing the “time of flight” implying the doublets or highly aggregated cells passing through. The combination of these four signals of each cell depicts “scattergram” with which cells are analyzed and categorized into subgroups by using software algorithms.

Fluorescence signals were utilized to differentiate WBC from the non-hematopoietic HF-BF cells showing higher fluorescence intensity than the cutoff value. HF-BF cells were not included in the WBC counts and the amounts of HF-BF cells were expressed as a ratio over the WBCs (HF-BF/100 WBCs, abbreviated as ‘HF-BF%’) or absolute cell counts (number of HF-BF/μL, abbreviated as ‘HF-BF#’). The total nucleated cell count (TNC) is the sum of the number of WBCs and HF-BF cells. Each type of WBCs was classified as following: neutrophils and eosinophils are counted as polymorphonuclear (PMN) cells; lymphocytes and monocytes are counted as mononuclear (MN) cells; and mesothelial cells, macrophages and malignant cells are counted as HF-BF cells.

**Novel scattergram gating algorithm**

The analyzed signals of the XN-BF were exported as FCS dataset for plotting WDF channel dot plots, or scattergrams. The analyses were performed using Flowing Software (Centre for Biotechnology, University of Turku, Finland: http://flowingsoftware.btk.fi/) [12]. Two following gating algorithm based on the WDF channel were combined: (1) Rule 1 was designed to detect the aggregated cells expressing higher forward scatter width signal and higher fluorescence signals than WBCs (as indicated in Area 1, Fig 1A); (2) Rule 2 was designed to detect middle range of fluorescence signals between WBCs and HF-BF cells with lower forward
Fig 1. Schematic illustration of the XN-BF gating algorithm. (A) Area 1 includes the aggregated cells due to the high forward scatter width signals that implies the long “time of flight” of the cells passing through the laser beam in the flow-cell. The HF-BF cells gated in Area 1 are considered as the
scatter signal compared to macrophages. This can differentiate the isolated malignant cells with similar size but generating higher fluorescence signals compared to the normal mononuclear cells (as indicated in Area 2, Fig 1B). BF samples that meet, at least, one criterion were detected as malignant cells.

**Manual microscopic analyses**

A hemocytometer (Fuchs-Rosenthal Rotterdam, Netherlands) was used for manual microscopic cell counting. For cell differentiation, cytospin slides were prepared by cytocentrifugation at 80 x g for 10 min. BF with high TNC (>1000 cells/μL) were diluted with Phosphate Buffered Saline (PBS) to obtain a concentration of 500–1000 cells/μL. Slides were stained by May-Grunwald-Giemsa. All slides were microscopically examined and performed differential count for 200 cells by an experienced medical technologist who was educated in hematopathology and cytopathology and a senior clinical pathologist. BF collection and analyses were performed in compliance with the CLSI H56-A guideline [13]. Concurrent pathological examinations were performed with Papanicolou (PAP) stained slides, followed by immunocytochemistry at an in-house pathology laboratory. Malignant cells were defined as ≥ Class IIIb (Papanicolaou class system) by the cytological examination.

**Statistics**

The accuracy to detect malignant cells among various methods were evaluated by Mann-Whitney U-test where appropriate. \( p < 0.05 \) was considered as statistically significant.

**Results**

**Comparison of the accuracy of the XN-BF analysis and the microscopic examinations in the hematology laboratory compared to the examinations in the cytology laboratory**

Table 1 summarizes the results of automated analyses and manual microscopic examinations. In the 92 BF samples, malignant cells were detected in 27 samples by the cytology examination. Although these two new algorithms (i.e., Rule 1 and Rule 2) are supposed to work complementally, there are some difference in the accuracy in the detection of malignant cells. Of the 27 malignant samples, five samples were detected by Rule 1 and 2 (18.5%), nine samples were detected by Rule 1 alone (33.3%), three samples were detected by Rule 2 alone (7.40%) and nine samples were not detected as malignant by either method (33.3%).

The accuracy of the XN-BF gating algorithm as well as the manual microscopic examinations in hematology laboratory in the detection of malignant cells were evaluated by a comparison with the cytological diagnosis. Table 2 summarized the results of accuracy by the three types of examinations performed in hematology laboratory showed high specificities (87.7–96.9%) but relatively low sensitivities (63.0–70.4%), with the highest accuracy of the WBC differential examination with May-Grunwald-Giemsa staining. We, then, analyzed the difference between true positive and false negative with the XN-BF gating algorithm in the cytology
Table 1. Characteristics of BF samples.

| Sample # | Material | Pathology | Class | Total cell # (μL) | WBC# (μL) | HF-BF# (μL) | HF-BF% (%) | XN algorithm | Microscopic examination |
|----------|----------|-----------|-------|------------------|-----------|-------------|------------|--------------|------------------------|
| 1        | PE†      | Adenocarcinoma | V     | 1828             | 998       | 830         | 83.2       | +            | +                      |
| 2        | PE       | Adenocarcinoma | V     | 1241             | 771       | 470         | 61.0       | +            | +                      |
| 3        | PE       | Adenocarcinoma | V     | 2460             | 1623      | 837         | 51.6       | +            | -                      |
| 4        | PE       | Adenocarcinoma | V     | 3597             | 2526      | 1071        | 42.4       | +            | +                      |
| 5        | PE       | Adenocarcinoma | V     | 3424             | 2723      | 701         | 25.7       | +            | +                      |
| 6        | PE       | Lung Adenocarcinoma | V     | 1469             | 342       | 1127        | 329.5      | +            | -                      |
| 7        | PE       | Malignant Lymphoma | V     | 1333             | 612       | 721         | 117.8      | +            | +                      |
| 8        | PE       | Adenocarcinoma | V     | 1528             | 1018      | 510         | 50.1       | +            | -                      |
| 9        | PE       | Adenocarcinoma | V     | 353              | 271       | 82          | 30.3       | +            | +                      |
| 10       | AF‡      | Adenocarcinoma | V     | 124              | 100       | 24          | 24.0       | +            | +                      |
| 11       | PE       | Small cell carcinoma | V     | 2124             | 1733      | 391         | 22.6       | +            | +                      |
| 12       | AF       | Adenocarcinoma | V     | 1404             | 1160      | 244         | 21.0       | +            | +                      |
| 13       | PE       | Adenocarcinoma | V     | 385              | 344       | 41          | 11.9       | +            | +                      |
| 14       | PE       | Lung Adenocarcinoma | V     | 1391             | 1320      | 71          | 5.4        | +            | +                      |
| 15       | PE       | Adenocarcinoma | V     | 218              | 124       | 94          | 75.8       | -            | +                      |
| 16       | PE       | Malignant Mesothelioma | V     | 426              | 358       | 68          | 19.0       | +            | +                      |
| 17       | PE       | Adenocarcinoma | V     | 609              | 494       | 115         | 23.3       | -            | -                      |
| 18       | PE       | Adenocarcinoma | V     | 297              | 277       | 20          | 7.2        | -            | +                      |
| 19       | PE       | Adenocarcinoma | IIIb  | 1682             | 1590      | 92          | 5.8        | -            | -                      |
| 20       | PE       | Adenocarcinoma | V     | 2773             | 2647      | 126         | 4.8        | -            | +                      |
| 21       | PE       | Adenocarcinoma | V     | 386              | 376       | 10          | 2.7        | -            | -                      |
| 22       | PE       | Lung Adenocarcinoma | V     | 3888             | 3806      | 82          | 2.2        | -            | -                      |
| 23       | PE       | Malignant Lymphoma | V     | 2927             | 2885      | 42          | 1.5        | -            | -                      |
| 24       | PE       | Adenocarcinoma | V     | 3786             | 3737      | 49          | 1.3        | -            | -                      |
| 25       | AF       | Adenocarcinoma | V     | 207              | 182       | 25          | 13.7       | -            | -                      |
| 26       | CSF§     | unknown       | V     | 909              | 373       | 536         | 143.7      | -            | +                      |
| 27       | CSF‡     | Medulloblastoma | V     | 53               | 50        | 3           | 6.0        | -            | +                      |
| 28       | PE       | N/D¶          | II    | 5692             | 4977      | 715         | 14.4       | +            | +                      |
| 29       | PE       | N/D          | II    | 5458             | 5240      | 218         | 4.2        | +            | -                      |
| 30       | PE       | N/D          | II    | 2785             | 2558      | 227         | 8.9        | +            | -                      |
| 31       | PE       | N/D          | II    | 1203             | 985       | 218         | 22.1       | -            | +                      |
| 32       | PE       | N/D          | IIb   | 2106             | 1825      | 281         | 15.4       | -            | -                      |
| 33       | PE       | N/D          | II    | 106              | 84        | 22          | 26.2       | -            | +                      |
| 34       | PE       | N/D          | II    | 217              | 193       | 24          | 12.4       | -            | -                      |
| 35       | PE       | N/D          | II    | 261              | 219       | 42          | 19.2       | -            | -                      |
| 36       | PE       | N/D          | III   | 89               | 85        | 4           | 4.7        | -            | -                      |
| 37       | PE       | N/D          | II    | 949              | 856       | 93          | 10.9       | -            | -                      |
| 38       | PE       | N/D          | II    | 3596             | 3500      | 96          | 2.7        | -            | -                      |
| 39       | PE       | N/D          | III   | 949              | 816       | 133         | 16.3       | -            | -                      |
| 40       | PE       | N/D          | III   | 48               | 45        | 3           | 6.7        | -            | -                      |
| 41       | PE       | N/D          | III   | 1008             | 994       | 14          | 1.4        | -            | -                      |
| 42       | PE       | N/D          | III   | 307              | 287       | 20          | 7.0        | -            | -                      |
| 43       | PE       | N/D          | III   | 242              | 219       | 23          | 10.5       | -            | -                      |
| 44       | PE       | N/D          | III   | 6760             | 6647      | 113         | 1.7        | -            | -                      |
| 45       | PE       | N/D          | III   | 7037             | 6668      | 369         | 5.5        | -            | -                      |

(Continued)
Table 1. (Continued)

| Sample # | Material | Pathology | Histological cancer type | Class | Total cell # (μL) | WBC# (μL) | HF-BF# (μL) | HF-BF% | XN algolrism | Malignancy | Microscopic examination | WBC differentiation | WBC count |
|----------|----------|-----------|--------------------------|-------|------------------|-----------|-------------|--------|-------------|------------|--------------------------|-------------------|----------|
| 46       | PE       | N/D       | IIb                      |       | 208              | 174       | 34          | 19.5   | -           | -          | -                       | -                 | -        |
| 47       | PE       | N/D       | IIb                      |       | 1114             | 1031      | 83          | 8.1    | -           | -          | -                       | -                 | -        |
| 48       | PE       | N/D       | II                       |       | 59               | 58        | 1           | 1.7    | -           | -          | -                       | -                 | -        |
| 49       | PE       | N/D       | II                       |       | 36               | 34        | 2           | 5.9    | -           | -          | -                       | -                 | -        |
| 50       | PE       | N/D       | II                       |       | 359              | 357       | 2           | 0.6    | -           | -          | -                       | -                 | -        |
| 51       | PE       | N/D       | II                       |       | 609              | 606       | 3           | 0.5    | -           | -          | -                       | -                 | -        |
| 52       | PE       | N/D       | II                       |       | 706              | 702       | 4           | 0.6    | -           | -          | -                       | -                 | -        |
| 53       | PE       | N/D       | II                       |       | 1914             | 1907      | 7           | 0.4    | -           | -          | -                       | -                 | -        |
| 54       | PE       | N/D       | II                       |       | 5216             | 5207      | 9           | 0.2    | -           | -          | -                       | -                 | -        |
| 55       | PE       | N/D       | II                       |       | 193              | 173       | 20          | 11.6   | -           | -          | -                       | -                 | -        |
| 56       | PE       | N/D       | II                       |       | 239              | 217       | 22          | 10.1   | -           | -          | -                       | -                 | -        |
| 57       | PE       | N/D       | II                       |       | 842              | 817       | 25          | 3.1    | -           | -          | -                       | -                 | -        |
| 58       | PE       | N/D       | II                       |       | 1753             | 1728      | 25          | 1.4    | -           | -          | -                       | -                 | -        |
| 59       | PE       | N/D       | II                       |       | 208              | 178       | 30          | 16.9   | -           | -          | -                       | -                 | -        |
| 60       | PE       | N/D       | II                       |       | 273              | 243       | 30          | 12.3   | -           | -          | -                       | -                 | -        |
| 61       | PE       | N/D       | II                       |       | 6651             | 6620      | 31          | 0.5    | -           | -          | -                       | -                 | -        |
| 62       | PE       | N/D       | II                       |       | 1014             | 972       | 42          | 4.3    | -           | -          | -                       | -                 | -        |
| 63       | PE       | N/D       | II                       |       | 6632             | 6578      | 54          | 0.8    | -           | -          | -                       | -                 | -        |
| 64       | PE       | N/D       | II                       |       | 509              | 452       | 57          | 12.6   | -           | -          | -                       | -                 | -        |
| 65       | AF       | N/D       | II                       |       | 1271             | 1197      | 74          | 6.2    | -           | -          | -                       | -                 | -        |
| 66       | PE       | N/D       | II                       |       | 777              | 699       | 78          | 11.2   | -           | -          | -                       | -                 | -        |
| 67       | PE       | N/D       | II                       |       | 1945             | 1838      | 107         | 5.8    | -           | -          | -                       | -                 | -        |
| 68       | PE       | N/D       | II                       |       | 2354             | 2234      | 120         | 5.4    | -           | -          | -                       | -                 | -        |
| 69       | PE       | N/D       | II                       |       | 2232             | 2107      | 125         | 5.9    | -           | -          | -                       | -                 | -        |
| 70       | AF       | N/D       | II                       |       | 548              | 399       | 149         | 37.3   | -           | -          | -                       | -                 | -        |
| 71       | PE       | N/D       | II                       |       | 1736             | 1470      | 266         | 18.1   | -           | -          | -                       | -                 | -        |
| 72       | PE       | N/D       | II                       |       | 3891             | 3539      | 352         | 9.9    | -           | -          | -                       | -                 | -        |
| 73       | PE       | N/D       | II                       |       | 3148             | 2746      | 402         | 14.6   | -           | -          | -                       | -                 | -        |
| 74       | AF       | N/D       | II                       |       | 268              | 253       | 15          | 5.9    | -           | -          | -                       | -                 | -        |
| 75       | PE       | N/D       | II                       |       | 1166             | 1143      | 23          | 2.0    | -           | -          | -                       | -                 | -        |
| 76       | PE       | N/D       | II                       |       | 1127             | 1096      | 31          | 2.8    | -           | -          | -                       | -                 | -        |
| 77       | CSF      | N/D       | III                      |       | 2                | 2         | 0           | 0.0    | -           | -          | -                       | -                 | -        |
| 78       | CSF      | N/D       | III                      |       | 8                | 8         | 0           | 0.0    | -           | -          | -                       | -                 | -        |
| 79       | CSF      | N/D       | III                      |       | 112              | 106       | 6           | 5.7    | -           | -          | -                       | -                 | -        |
| 80       | CSF      | N/D       | Negative                 |       | 1                | 1         | 0           | 0.0    | -           | -          | -                       | -                 | -        |
| 81       | CSF      | N/D       | Negative                 |       | 1                | 1         | 0           | 0.0    | -           | -          | -                       | -                 | -        |
| 82       | CSF      | N/D       | Negative                 |       | 1                | 1         | 0           | 0.0    | -           | -          | -                       | -                 | -        |
| 83       | CSF      | N/D       | Negative                 |       | 2                | 2         | 0           | 0.0    | -           | -          | -                       | -                 | -        |
| 84       | CSF      | N/D       | Negative                 |       | 2                | 2         | 0           | 0.0    | -           | -          | -                       | -                 | -        |
| 85       | CSF      | N/D       | Negative                 |       | 2                | 2         | 0           | 0.0    | -           | -          | -                       | -                 | -        |
| 86       | CSF      | N/D       | Negative                 |       | 11               | 10        | 1           | 10.0   | -           | -          | -                       | -                 | -        |
| 87       | CSF      | N/D       | Negative                 |       | 7                | 7         | 0           | 0.0    | -           | -          | -                       | -                 | -        |
| 88       | CSF      | N/D       | Negative                 |       | 246              | 241       | 5           | 2.1    | -           | -          | -                       | -                 | -        |
| 89       | CSF      | N/D       | Negative                 |       | 115              | 115       | 0           | 0.0    | -           | -          | -                       | -                 | -        |
| 90       | CSF      | N/D       | Negative                 |       | 23               | 22        | 1           | 4.5    | -           | -          | -                       | -                 | -        |

(Continued)
positive malignant BF samples. As shown in Table 3, the false negative samples contained significantly lower number of HF-BF cells ($p = 0.008$) than the true positive samples, which indicates that a small malignant cells number is at least one of the causes of the false negative with the XN-BF gating algorithm. No significant difference was observed among these methods in total cell numbers or WBC numbers.

The examples in the detection of malignant cells by the new algorithms

As described in the methods, the XN-BF gating algorithm is supposed to detect malignant cells with relatively large size and/or cell clumps by Rule 1, and cells contains condensed intracellular contents such as RNAs and DNAs are supposed to be detected by Rule 2. Fig 2 shows representative scattergrams of XN-BF and corresponding May-Grunwald-Giemsa staining photomicrographs. Fig 2A through C show representative body fluids with true positive results of the XN-BF gating algorithm. Malignant cells detected by Rule 1 and/or Rule 2. Fig 2A shows a malignant PE (sample #4, Table 1) detected as malignancy by the XN-BF gating algorithm (positive by both Rule 1 and 2) containing highly aggregated adenocarcinoma cells (88.7% by microscopic differential count). Fig 2B shows a malignant PE (sample #13, Table 1) detected as malignancy (Rule 1 positive, but Rule 2 negative) with the isolated cluster of adenocarcinoma cells (11.8% by the microscopic differential count). Fig 2C is a malignant mesothelioma PE (sample #16, Table 1) detected as malignancy (Rule 1 negative, but Rule 2 positive) containing malignant cells with isolated and sparse form (7.6% by the microscopic differential count). Fig 2D shows a malignant PE (sample #18, Table 1) interpreted as negative for malignancy by the XN-BF gating algorithm (negative by both Rule 1 and 2) containing small number of isolated adenocarcinoma cells (1.5% by the microscopic differential count).

Discussion

In this study, we investigated the accuracy of a newly developed XN-BF gating algorithm in the detection of malignant cells using Sysmex XN-1000 automated hematology analyzer. As described in the method section, this algorithm was designed to detect malignant cells by

Table 2. Performance of examinations in hematology laboratory in the detection of BF malignancy compared with cytological diagnosis.

| Type of examination                              | Sensitivity (%) | Specificity (%) | Positive Predictive Value (%) | Negative Predictive Value (%) |
|--------------------------------------------------|-----------------|-----------------|------------------------------|------------------------------|
| XN-BF gating algorithm                           | 63.0            | 87.7            | 68.0                         | 85.1                         |
| Microscopic WBC differential (May-Grunwald Giemsa stain) | 70.4            | 96.9            | 90.5                         | 88.7                         |
| Microscopic WBC count (Fuchs-Rosenthal)          | 66.7            | 92.3            | 78.3                         | 87.0                         |

https://doi.org/10.1371/journal.pone.0190886.t002
addition of two detection rules to the conventional Sysmex XN-BF mode: (1) measuring passing time that is affected by cell clumps; and (2) measuring fluorescence intensity reflected by cytoplasmic organelles and nucleus contents. Whereas the sophisticated algorithms are developed for automatic computational algorithms of flowcytometry [14], our gating analyses were performed manually and our system is not using various CD markers or other special staining. This study is attempting to develop a relatively simple and more accurate detection system compared to the conventional manual microscopic examination that performed by simple May-Grunwald-Giemsa staining in hematology laboratories rather than full cytology examination in pathology laboratories at stage.

We and others have reported the difficulties to distinguish malignant cells from benign ones containing macrophages and mesothelial cells by the conventional Sysmex HF-BF mode because of its low specificity [8, 13]. This is mainly due to the use of only two detection algorithms: (1) forward scattering signal detection that can evaluate size of cells; and (2) side scattering signal detection algorithm that can detect the reflection of laser beams by cyto organelles. Recently, Labaere et al. analyzed BF samples by HF-BF mode of Sysmex XN-2000 with a cut off level of 17 HF-BF cells /μL to detect malignant cells, and reported still relatively low specificity of 61% compared to the conventional microscopic examination with May-Grunwald Giemsa stained slides performed in hematology laboratory [8]. Malignant cells show several unique features compared to normal blood cells: (1) these cells are usually larger than normal hematocytes; (2) these cells contain more DNAs and RNAs than normal hematocytes [15]; (3) these cells’ cytoorganelles are often more complicated than non-malignant cells; and (4) these cells have tendency to form cell clumps. We, therefore, developed a new algorithm by addition of two parameters, Rule 1 and Rule 2, to detect malignant cells more specifically, and achieved markedly high specificity of 87.8% compared to the conventional microscopic differential count with May-Grunwald Giemsa stained slides performed in hematology laboratory. This means that the XN-BF gating algorithm reduces unnecessary microscopic analyses. On the other hands, we observed false negative results in the cases with small number of malignant cells. Further studies using more samples obtained from various kinds of body fluid samples are warranted to validate our current estimation. We are planning to expand our study to incorporate data from multiple centers, and adding more developed technology such as automated digital morphological analyzer, DI-60 which is equipped with Sysmex XN series. The combinational usage of automated high definition microscopy images may improve both specificity and sensitivity. The number of similar studies using XN-series automated analyzers is rapidly increasing all over the world. Since 2012, more than 100 studies using the XN-series have been published (referred in PubMed), and the number of studies is increasing year-by-year. To date, more than 20,000 XN-series hematology analyzers were shipped to all over the world.

### Table 3. Sysmex XN-BF data and performance of examinations in hematology laboratory to detect malignancy.

| XN-BF data | XN-BF gating algolrism | Microscopic WBC differential | Microscopic WBC count |
|------------|------------------------|-----------------------------|-----------------------|
|            | True positive (n = 15) | False negative (n = 11)    | True positive (n = 18) | False negative (n = 8) |
| Total cell # (/μL) | 1457 ± 265 | 1592 ± 448 | 1485 ± 281 | 1698 ± 455 |
| WBC # (/μL) | 1001 ± 203 | 1492 ± 452 | 1108 ± 251 | 1488 ± 447 |
| HF-BF # (/μL) | 455 ± 96 | 100 ± 45 | 377 ± 84 | 210 ± 106 |
| HF-BF % (%) | 61±19 | 19 ± 13 | 54 ± 17 | 19 ± 7 |

The data are presented as mean ± SEM.

https://doi.org/10.1371/journal.pone.0190886.t003
including approximately 5000 of XN analyzers to the U.S. Thus, we believe that the XN-series analyzers have been used in many laboratories as automated hematology analyzer.

In this study, we observed that the tested different hematological examinations, including the XN-BF gating algorithm and the manual microscopic examinations in hematology laboratory, showed similar sensitivity and specificity compared to the cytological examinations. Whereas the accuracy of the XN-BF gating mode needs to be improved to attain higher sensitivity, this system might facilitate a feature upgrade of the automated hematology analyzer to detect malignant cells in BF.

As the study limitations, this is a single center study with relatively small size samples. The number of samples and type of malignant cells for each type of BF were limited. Although we examined cells from same samples for automated analyses and microscopic examinations in hematology laboratory, it was not possible to analyze exact the same cells for cytopathology laboratory since it is not feasible to collect a single cell from flow cytometry to fix and stain for cytopathological examinations. In addition, microscopic examinations by interexaminers’ and/or intraexaminers’ inconsistency could not be completely removed even though two well-trained examiners performed the studies. These issues cannot be avoided in any laboratories, and we are increasing number of samples for each kind of BF for the future study.

In conclusion, the XN-BF gating algorithm for the BF malignancy diagnosis may have a potential to be the alternative method to the morphological examination, which can benefit for hematology laboratories to screen malignant cells rapidly without requiring additional sample preparation procedure and with minimal operator bias. Currently, manual microscopic examination is the golden standard. However, in the future, we believe that accuracy and quality of automated analyses of BF samples can be further improved with the technology development, and that this type of automated detecting system can serve as an adjunct quality control system.

**Supporting information**

S1 File. Corresponds to the raw data for scattergrams in Fig 2A. (FCS)

S2 File. Corresponds to the raw data for scattergrams in Fig 2B. (FCS)

S3 File. Corresponds to the raw data for scattergrams in Fig 2C. (FCS)

S4 File. Corresponds to the raw data for scattergrams in Fig 2D. (FCS)

**Author Contributions**

Conceptualization: Yoko Tabe, Aya Konishi.
Data curation: Hiroyuki Takemura, Konobu Kimura, Toshihiro Takahashi, Haeun Yang, Koji Tsuchiya, Kinya Uchihashi.

Formal analysis: Tomohiko Ai, Hiroyuki Takemura, Konobu Kimura, Toshihiro Takahashi, Haeun Yang, Koji Tsuchiya, Aya Konishi, Kinya Uchihashi.

Investigation: Aya Konishi, Kinya Uchihashi.

Methodology: Kinya Uchihashi.

Project administration: Takashi Horii, Akimichi Ohsaka.

Supervision: Tomohiko Ai, Takashi Horii, Akimichi Ohsaka.

Validation: Tomohiko Ai, Takashi Horii, Akimichi Ohsaka.

Writing – original draft: Tomohiko Ai.

References

1. Dekker A, Bupp PA. Cytology of serous effusions. An investigation into the usefulness of cell blocks versus smears. Am J Clin Pathol. 1978; 70(6):855–60. Epub 1978/12/01. PMID: 364975.

2. Jerz JL, Donohue RE, Mody RR, Schwartz MR, Mody DR, Zieske AW. Detection of malignancy in body fluids: a comparison of the hematology and cytology laboratories. Arch Pathol Lab Med. 2014; 138(5):651–7. Epub 2014/05/03. https://doi.org/10.5858/arpa.2013-0295-OA PMID: 24786122.

3. Ben-Ezra J, Staschner IF, Harris AC, Bork L, Frable WJ. Comparison of the clinic microscopy laboratory with the cytopathology laboratory in the detection of malignant cells in body fluids. Am J Clin Pathol. 1994; 102(4):439–42. Epub 1994/10/01. PMID: 7942600.

4. Kendall B, Dunn C, Solanki P. A comparison of the effectiveness of malignancy detection in body fluid examination by the cytopathology and hematology laboratories. Arch Pathol Lab Med. 1997; 121(9):976–9. Epub 1997/09/26. PMID: 9302931.

5. Doherty CM, Forbes RB. Diagnostic Lumbar Puncture. Ulster Med J. 2014; 83(2):93–102. Epub 2014/07/31. PMID: 25075138; PubMed Central PMCID: PMCPMC4113153.

6. Franchini M, Di Minno MN, Coppola A. Disseminated intravascular coagulation in hematologic malignancies. Semin Thromb Hemost. 2010; 36(4):388–403. Epub 2010/07/09. https://doi.org/10.1055/s-0030-1254048 PMID: 20614391.

7. Seghezzi M, Buoro S, Manenti B, Mecca T, Ferrari R, Zappala G, et al. Optimization of Cellular analysis of Synovial Fluids by optical microscopy and automated count using the Sysmex XN Body Fluid Mode. Clin Chim Acta. 2016; 462:41–8. Epub 2016/10/19. https://doi.org/10.1016/j.cca.2016.08.018 PMID: 27581597.

8. Labaere D, Boeckx N, Geerts I, Moens M, Van den Driessche M. Detection of malignant cells in serous body fluids by counting high-fluorescent cells on the Sysmex XN-2000 hematology analyzer. Int J Lab Hematol. 2015; 37(5):715–22. Epub 2015/06/16. https://doi.org/10.1111/ijlh.12393 PMID: 26074270.

9. Fleming C, Russcher H, Brouwer R, Lindemans J, de Jonge R. Evaluation of Sysmex XN-1000 High-Sensitive Analysis (hsA) Research Mode for Counting and Differentiating Cells in Cerebrospinal Fluid. Am J Clin Pathol. 2016; 145(3):299–307. Epub 2016/04/29. https://doi.org/10.1093/ajcp/aqv093 PMID: 27124911.

10. Fleming C, Brouwer R, Lindemans J, de Jonge R. Validation of the body fluid module on the new Sysmex XN-1000 for counting blood cells in cerebrospinal fluid and other body fluids. Clin Chim Lab Med. 2012; 50(10):1791–8. Epub 2012/10/24. https://doi.org/10.1515/cclm-2011-0927 PMID: 23089709.

11. Cho YU, Chi HS, Park SH, Jang S, Kim YJ, Park CJ. Body fluid cellular analysis using the Sysmex XN-2000 automatic hematology analyzer: focusing on malignant samples. Int J Lab Hematol. 2015; 37(3):346–56. Epub 2014/09/13. https://doi.org/10.1111/ijlh.12292 PMID: 25212101.

12. Sahraneshin Samani F, Moore JK, Khosravani P, Ebrahimi M. Features of free software packages in flow cytometry: a comparison between four non-commercial software sources. Cytotechnology. 2014; 66(4):555–9. Epub 2013/07/11. https://doi.org/10.1007/s10616-013-9609-8 PMID: 23839300; PubMed Central PMCID: PMCPMC4082777.

13. Takemura H, Tabe Y, Ishii K, Kobayashi Y, Kuno Y, Horii T, et al. [Evaluation of capability of cell count and detection of tumor cells in cerebrospinal and body fluids by automated hematology analyzer]. Rinsho Byori. 2010; 58(6):559–64. Epub 2010/07/29. PMID: 20662266.
14. Saeyes Y, Gassen SV, Lambrecht BN. Computational flow cytometry: helping to make sense of high-dimensional immunology data. Nat Rev Immunol. 2016; 16(7):449–62. Epub 2016/06/21. https://doi.org/10.1038/nri.2016.56 PMID: 27320317.

15. Ho TY, Witz G. Increased gene expression in human promyeloid leukemia cells exposed to trans,trans-muconaldehyde, a hematotoxic benzene metabolite. Carcinogenesis. 1997; 18(4):739–44. Epub 1997/04/01. PMID: 9111208.